Sponsors (6)
Official title: To amend the Public Health Service Act to provide for greater investments in research on rare diseases and conditions disproportionately affecting minority populations, and for other purposes.
Introduced February 27, 2025 by Marilyn Strickland · Last progress February 27, 2025
The bill concentrates federal attention, funding, and coordination to improve research, diagnosis, workforce capacity, and outreach for rare diseases affecting racial/ethnic minority and tribal populations — but it will raise federal costs, create administrative and privacy challenges, and risks uneven or delayed benefits without careful implementation and funding.
Racial and ethnic minority communities, Native American and Alaska Native people, and other patients with rare diseases will get better-targeted research, screening, diagnosis, and treatment options through new grants, studies, and tailored programs.
Federal agencies (NIH, CDC, FDA, HHS) and Congress will gain improved coordination, data collection, and near-term reports that create accountability and a clearer pathway for policy fixes to improve rare-disease equity and access.
Researchers, academic institutions, and community organizations will receive new targeted grant funding and appropriations to build sustained research capacity on rare diseases affecting minority and tribal populations.
Taxpayers and the federal budget will face increased spending to fund new grants, reports, scholarships, loan repayments, and programs unless offsets are specified.
Small tribal clinics, community organizations, academic programs, and federal agencies may face substantial administrative burden and diverted staff time to apply for, manage, and implement grants, plans, and reports, potentially reducing capacity for other programs.
Collecting and coordinating sensitive health and genetic data to identify disparities raises privacy and data-security risks for participants if robust safeguards, consent processes, and protections are not maintained.
Based on analysis of 11 sections of legislative text.
Authorizes federal grants, planning, workforce training, outreach, and interagency coordination to improve research, data, care, and equity for rare diseases in minority and Tribal populations.
Creates new federal programs, grants, planning, research coordination, workforce training, education, and reporting to improve understanding, diagnosis, treatment, and equity for rare diseases that disproportionately affect minority populations — including Tribal and Urban Indian communities. It directs HHS (through NIH, CDC, FDA, IHS, and HRSA) to fund Tribal epidemiology centers, expand NIH coordination and research on rare-disease health equity, build clinical training and loan repayment/scholarship programs, run public education campaigns, and produce several reports to Congress on barriers, data gaps, and clinical-trial representation. The bill primarily authorizes grant programs, coordination committees, plans, and reports; it does not itself appropriate new funds but requires Congress to authorize and appropriate amounts to carry out the programs and directs agencies to develop implementation plans and timelines (many reports due within 180 days to 2 years).